KIYATEC

KIYATEC has developed primary human derived 3D microtumors designed to more accurately predict human response to cancer drugs in an ex vivo system. The heterotypic, 3D perfused co-cultures established the use of a systemic strategy of adopting optimized scaffolds, cell types, and media conditions to KIYATEC’s novel 3D perfusion bioreactor, the 3DKUBE™.
Website: kiyatec.com

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To receive the lastest news and updates from the field, subscribe to the newsletter here.

View the top 3 talks from PMWC here (password: top-videos).

Once you sign up you will get access to the top 3 talks from January’s PMWC.
We hate spam too, unsubscribe at any time.

Do not alert me again.